Neobe Therapeutics
Engineered live bacteria that break down tumour barriers so immunotherapy can reach solid tumours
About Neobe Therapeutics
Neobe Therapeutics is a UK synthetic biology biotech founded in 2021 through a Deep Science Ventures venture-creation programme. It engineers non-pathogenic bacteria that colonise solid tumours and release enzymes, such as hyaluronidase, that break down the fibrotic stroma around them, so immune cells and existing immunotherapies can reach immune-excluded tumours. Its lead programme NEO22 targets colorectal, pancreatic and breast cancer and is in preclinical development, with an IND filing planned for 2028. The lab is at Stevenage Bioscience Catalyst.
Founders
Annelise Soulier
Co-founder and CSO
Molecular biologist and bacterial engineer, formerly at Prokarium, with more than 7 years of work on bacterial therapeutics. Co-inventor of patented engineered live biotherapeutics that are now in clinical trials.
Pedro Correa de Sampaio
Co-founder and CEO
Tumour microenvironment researcher with more than 12 years of research experience, including at the CRUK Cambridge Institute and MD Anderson Cancer Center. He previously worked on immuno-oncology cell therapies at Triumvira Immunologics.
- Biotech & Life Sciences
- Stevenage, UK
- Seed
- 2021
- €9.4m
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| Seed | Undisclosed | ARC Ventures | |
| Pre-seed | Undisclosed | 2048 Ventures |
